COMPASS Pathways plc (CMPS)

Market Cap	486.88M
Revenue (ttm)	n/a
Net Income (ttm)	-118.46M
Shares Out	61.94M
EPS (ttm)	-2.32
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,492,650
Open	8.10
Previous Close	8.10
Day's Range	7.64 - 8.10
52-Week Range	5.01 - 12.75
Beta	2.49
Analysts	Strong Buy
Price Target	45.83 (+483.08%)
Earnings Date	May 9, 2024

About CMPS

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United...

• Industry: Medical Care Facilities
• Sector: Healthcare
• IPO Date: Sep 18, 2020
• Employees: 186
• Stock Exchange: NASDAQ
• Ticker Symbol: CMPS

Analyst Forecast

According to 7 analysts, the average rating for CMPS stock is "Strong Buy." The 12-month stock price forecast is $45.83, which is an increase of 483.08% from the latest price.

Price Target

$45.83

(483.08% upside)

Analyst Consensus: Strong Buy